LifeStance Health Gr Analyst Ratings
LifeStance Health Gr Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 21.58% | JP Morgan | $9 → $10 | Maintains | Neutral |
| 07/13/2023 | 21.58% | Morgan Stanley | $10 → $10 | Reiterates | Overweight → Overweight |
| 05/19/2023 | 9.42% | Goldman Sachs | $8 → $9 | Maintains | Neutral |
| 05/11/2023 | 21.58% | Morgan Stanley | $8 → $10 | Maintains | Overweight |
| 01/06/2023 | -2.74% | Morgan Stanley | → $8 | Upgrades | Equal-Weight → Overweight |
| 11/15/2022 | -2.74% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
| 11/14/2022 | -2.74% | Cowen & Co. | $10 → $8 | Maintains | Outperform |
| 11/07/2022 | — | Jefferies | Assumes | → Buy | |
| 08/22/2022 | 21.58% | Cowen & Co. | $11 → $10 | Maintains | Outperform |
| 05/10/2022 | -2.74% | Morgan Stanley | $10 → $8 | Maintains | Equal-Weight |
| 03/21/2022 | 21.58% | Goldman Sachs | $15 → $10 | Maintains | Neutral |
| 03/17/2022 | 21.58% | UBS | $19 → $10 | Downgrades | Buy → Neutral |
| 12/17/2021 | 21.58% | Morgan Stanley | $15 → $10 | Maintains | Equal-Weight |
| 11/09/2021 | 45.9% | JP Morgan | $24 → $12 | Downgrades | Overweight → Neutral |
| 09/10/2021 | 118.84% | Cowen & Co. | → $18 | Initiates Coverage On | → Outperform |
| 08/16/2021 | 94.53% | Morgan Stanley | $36 → $16 | Downgrades | Overweight → Equal-Weight |
| 07/06/2021 | 313.37% | UBS | → $34 | Initiates Coverage On | → Buy |
| 07/06/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/06/2021 | 337.69% | Morgan Stanley | → $36 | Initiates Coverage On | → Overweight |
| 07/06/2021 | 337.69% | JP Morgan | → $36 | Initiates Coverage On | → Overweight |
| 07/06/2021 | 203.95% | Goldman Sachs | → $25 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月10日 | 21.58% | 摩根大通 | $9→$10 | 维护 | 中性 |
| 07/13/2023 | 21.58% | 摩根士丹利 | $10→$10 | 重申 | 超重→超重 |
| 2023年05月19日 | 9.42% | 高盛 | $8→$9 | 维护 | 中性 |
| 2023年05月11日 | 21.58% | 摩根士丹利 | $8→$10 | 维护 | 超重 |
| 01/06/2023 | -2.74% | 摩根士丹利 | →$8 | 升级 | 等重→超重 |
| 2022年11月15日 | -2.74% | 高盛 | $9→$8 | 维护 | 中性 |
| 2022年11月14日 | -2.74% | 考恩公司 | $10→$8 | 维护 | 跑赢大盘 |
| 11/07/2022 | - | 杰富瑞 | 假设 | →购买 | |
| 2022/08/22 | 21.58% | 考恩公司 | $11→$10 | 维护 | 跑赢大盘 |
| 2022年05月10日 | -2.74% | 摩根士丹利 | $10→$8 | 维护 | 等重 |
| 03/21/2022 | 21.58% | 高盛 | $15→$10 | 维护 | 中性 |
| 03/17/2022 | 21.58% | 瑞银集团 | $19→$10 | 评级下调 | 购买→中性 |
| 2021/12/17 | 21.58% | 摩根士丹利 | $15→$10 | 维护 | 等重 |
| 11/09/2021 | 45.9% | 摩根大通 | $24→$12 | 评级下调 | 超重→中性 |
| 09/10/2021 | 118.84% | 考恩公司 | →$18 | 开始承保 | →跑赢大盘 |
| 08/16/2021 | 94.53% | 摩根士丹利 | $36→$16 | 评级下调 | 超重→等重 |
| 07/06/2021 | 313.37% | 瑞银集团 | →$34 | 开始承保 | →购买 |
| 07/06/2021 | - | 威廉·布莱尔 | 开始承保 | →跑赢大盘 | |
| 07/06/2021 | 337.69% | 摩根士丹利 | →$36 | 开始承保 | →超重 |
| 07/06/2021 | 337.69% | 摩根大通 | →$36 | 开始承保 | →超重 |
| 07/06/2021 | 203.95% | 高盛 | →$25 | 开始承保 | →中性 |
What is the target price for LifeStance Health Gr (LFST)?
LifeStance Health Gr(LFST)的目标价格是多少？
The latest price target for LifeStance Health Gr (NASDAQ: LFST) was reported by JP Morgan on August 10, 2023. The analyst firm set a price target for $10.00 expecting LFST to rise to within 12 months (a possible 21.58% upside). 9 analyst firms have reported ratings in the last year.
摩根大通于2023年8月10日报道了LifeStance Health Gr(纳斯达克：LFST)的最新目标价。这家分析公司将目标价定为10.00美元，预计LFST将在12个月内升至(可能上涨21.58%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for LifeStance Health Gr (LFST)?
LifeStance Health Gr(LFST)的最新分析师评级是多少？
The latest analyst rating for LifeStance Health Gr (NASDAQ: LFST) was provided by JP Morgan, and LifeStance Health Gr maintained their neutral rating.
分析师对LifeStance Health Gr(纳斯达克代码：LFST)的最新评级由摩根大通提供，LifeStance Health Gr维持中性评级。
When is the next analyst rating going to be posted or updated for LifeStance Health Gr (LFST)?
LifeStance Health Gr(LFST)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LifeStance Health Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LifeStance Health Gr was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与LifeStance Health Gr的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。LifeStance Health Gr的上一次评级是在2023年8月10日提交的，所以你应该预计下一次评级将在2024年8月10日左右提供。
Is the Analyst Rating LifeStance Health Gr (LFST) correct?
分析师对LifeStance Health Gr(LFST)的评级正确吗？
While ratings are subjective and will change, the latest LifeStance Health Gr (LFST) rating was a maintained with a price target of $9.00 to $10.00. The current price LifeStance Health Gr (LFST) is trading at is $8.23, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的LifeStance Health Gr(LFST)评级保持不变，目标价在9.00美元至10.00美元之间。LifeStance Health Gr(LFST)目前的交易价格为8.23美元，超出了分析师的预测区间。